Reported results
- Jakafi/Jakafi XR net sales were $827 million in the third quarter of 2026.
- Opzelura cream net sales were $255 million in the third quarter of 2026.
- Hematology and Oncology portfolio net sales were $235 million in the third quarter of 2026.
- GAAP research and development expenses were $1.79 billion and non-GAAP research and development expenses were $1.75 billion for the third quarter of 2026.
- GAAP SG&A expenses were $364.3 million and non-GAAP SG&A expenses were $339.1 million for the third quarter of 2026.
- GAAP and non-GAAP cost of sales were $108.7 million and $102.2 million, respectively, for the third quarter of 2026.
Guidance
- Full year 2026 Opzelura net sales guidance: $1,100 - $1,120 million
- Full year 2026 Hematology and Oncology net sales guidance: $890 - $910 million
- Full year 2026 total net sales guidance: $5,210 - $5,300 million
Notes
The third quarter of 2026 includes a one-time $1.23 billion IPR&D expense related to the acquisition of Vega Therapeutics.
Price and volatility reaction
The stock moved -0.1% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -5.1 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 116.87 | 2026-10-28 |
| Close after release | 116.8 | 2026-10-29 |
| Realised move | -0.1% | close to close |
| 30d ATM IV change | -5.1 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.
